Affimed NV (Nasdaq:AFMD)
November 1st, 2018
With markets going up Affimed NV went up $0.56 Thursday, a 17.78% increase, closing at $3.71. The stock continues to trade well at 223% of its 52 week low of $1.15. Affimed NV bounced 27.38% between low and high. Two technical ‘scores’ for companies to be wary of are the Altman Z1 and the Piotroski2 scores. AFMD scored quite low for both, which could be indicators of trouble down the road (the Altman Z-Score is 1.34, and the Piotroski Score is 2). In addition to finishing higher, trading volumes were solid at 248% of normal which can indicate investors see opportunities.
AFMD outperformed the rest of the Healthcare sector which went up 1.31% today.
The market sectors were mixed Thursday with a majority of the sectors trending up. Materials saw the biggest increase of the day (3.02%), while Utilities saw the biggest drop (0.53%). Information Technology has seen the biggest year-to-date gain at 9.90%. The biggest loss this year has been the Materials sector dropping 13%.
Materials saw the biggest turnaround from its 5-day performance of 4.09%, as it went up 3.02%. Utilities saw a turn around from its 5-day performance of -2.71% trading down 0.53%.
- Materials went up with a 3.02% change.
- Consumer Discretionary went up with a 2.23% change.
- Industrials went up with a 1.72% change.
- Healthcare went up with a 1.31% change.
- Information Technology went up with a 1.20% change.
- Energy went up with a 0.83% change.
- Consumer Staples went up with a 0.48% change.
- Real Estate went up with a 0.46% change.
- Financials went up with a 0.45% change.
- Communication Services went up with a 0.14% change.
- Utilities went down with a -0.53% change.
Affimed NV Info
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company’s products include AFM24, a NK-cell bispecific antibody targets EGFR-wild type represents a validated antigen expressed by various solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
All amounts in USD unless otherwise indicated
(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that Affimed NV’s score is 1.34) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.
(2) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Affimed NV’s score is ), and 9 is the best.
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.